Eledon Pharmaceuticals, Inc. (ELDN) vs Lyell Immunopharma, Inc. (LYEL)
A side-by-side comparison of Eledon Pharmaceuticals, Inc. and Lyell Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ELDN
Eledon Pharmaceuticals, Inc.
$2.45HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT
LYEL
Lyell Immunopharma, Inc.
$8.75HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — ELDN vs LYEL
growth of $100 · dividends reinvested · last 5yELDN -68.9% (-20.8%/yr)LYEL -97.3% (-51.5%/yr)ELDN compounded faster over this window
Log scale — wide-divergence pair
ELDN LYEL
ELDN vs LYEL: by the numbers
- •LYEL is the larger company ($214M vs $189M market cap).
- •Both run net losses; ELDN's is the smaller (0.00% vs -920285.19% net margin).
Metrics side by side
Valuation
| Metric | ELDN | LYEL |
|---|---|---|
| P/S ratio | N/A | 7941.23 |
| P/B ratio | 5.73 | 0.92 |
Profitability
| Metric | ELDN | LYEL |
|---|---|---|
| Gross margin | 0.00% | -31952.78% |
| Operating margin | 0.00% | -566038.89% |
| Net margin | 0.00% | -920285.19% |
| ROE | -136.83% | -106.27% |
| ROIC | -74.02% | -70.80% |
Growth (annualized)
| Metric | ELDN | LYEL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -68.32% |
| Total return CAGR (5Y) | -15.17% | -48.18% |
Frequently asked
- How have ELDN and LYEL total returns compared?
- Over the past 5 years, ELDN delivered -15.17% and LYEL delivered -48.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.